LymphedemaV1, France, Analysis, bibRecord, 000504

Infliximab for hidradenitis suppurativa: report of seven consecutive patients

Identifieur interne : 000504 ( France/Analysis ); précédent : 000503; suivant : 000505

Infliximab for hidradenitis suppurativa: report of seven consecutive patients

Auteurs : Alain Dupuy [France] ; Laurence Fardet [France] ; Delphine Kerob [France] ; Annabelle Levy [France] ; Hervé Bachelez [France] ; Patrice Morel [France] ; Celeste Lebbe [France]

Source :

Experimental Dermatology [ 0906-6705 ] ; 2006-06.

RBID : ISTEX:8A06656ED8C310D1C1359881CEBB4BFF5981988C

Abstract

Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS). Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow‐up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab. Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked (n = 1), moderate (n = 4) or null (n = 2). At week 10, five patients were evaluated and judged this efficacy as marked (n = 2), moderate (n = 2) or null (n = 1). The mean Skindex‐29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10. Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.

Url:

https://api.istex.fr/document/8A06656ED8C310D1C1359881CEBB4BFF5981988C/fulltext/pdf

DOI: 10.1111/j.0906-6705.2006.0436o.x

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 004109
to stream Istex, to step Curation: 004109
to stream Istex, to step Checkpoint: 001733
to stream Main, to step Merge: 007E42
to stream Main, to step Curation: 007C49
to stream Main, to step Exploration: 007C49
to stream France, to step Extraction: 000504

Links to Exploration step

ISTEX:8A06656ED8C310D1C1359881CEBB4BFF5981988C

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title>
<author><name sortKey="Dupuy, Alain" sort="Dupuy, Alain" uniqKey="Dupuy A" first="Alain" last="Dupuy">Alain Dupuy</name>
</author>
<author><name sortKey="Fardet, Laurence" sort="Fardet, Laurence" uniqKey="Fardet L" first="Laurence" last="Fardet">Laurence Fardet</name>
</author>
<author><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name>
</author>
<author><name sortKey="Levy, Annabelle" sort="Levy, Annabelle" uniqKey="Levy A" first="Annabelle" last="Levy">Annabelle Levy</name>
</author>
<author><name sortKey="Bachelez, Herve" sort="Bachelez, Herve" uniqKey="Bachelez H" first="Hervé" last="Bachelez">Hervé Bachelez</name>
</author>
<author><name sortKey="Morel, Patrice" sort="Morel, Patrice" uniqKey="Morel P" first="Patrice" last="Morel">Patrice Morel</name>
</author>
<author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8A06656ED8C310D1C1359881CEBB4BFF5981988C</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1111/j.0906-6705.2006.0436o.x</idno>
<idno type="url">https://api.istex.fr/document/8A06656ED8C310D1C1359881CEBB4BFF5981988C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004109</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004109</idno>
<idno type="wicri:Area/Istex/Curation">004109</idno>
<idno type="wicri:Area/Istex/Checkpoint">001733</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001733</idno>
<idno type="wicri:doubleKey">0906-6705:2006:Dupuy A:infliximab:for:hidradenitis</idno>
<idno type="wicri:Area/Main/Merge">007E42</idno>
<idno type="wicri:Area/Main/Curation">007C49</idno>
<idno type="wicri:Area/Main/Exploration">007C49</idno>
<idno type="wicri:Area/France/Extraction">000504</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Infliximab for hidradenitis suppurativa: report of seven consecutive patients</title>
<author><name sortKey="Dupuy, Alain" sort="Dupuy, Alain" uniqKey="Dupuy A" first="Alain" last="Dupuy">Alain Dupuy</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hopital Saint‐Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fardet, Laurence" sort="Fardet, Laurence" uniqKey="Fardet L" first="Laurence" last="Fardet">Laurence Fardet</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hopital Saint‐Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hopital Saint‐Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levy, Annabelle" sort="Levy, Annabelle" uniqKey="Levy A" first="Annabelle" last="Levy">Annabelle Levy</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hopital Saint‐Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bachelez, Herve" sort="Bachelez, Herve" uniqKey="Bachelez H" first="Hervé" last="Bachelez">Hervé Bachelez</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hopital Saint‐Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morel, Patrice" sort="Morel, Patrice" uniqKey="Morel P" first="Patrice" last="Morel">Patrice Morel</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hopital Saint‐Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hopital Saint‐Louis, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Experimental Dermatology</title>
<title level="j" type="alt">EXPERIMENTAL DERMATOLOGY</title>
<idno type="ISSN">0906-6705</idno>
<idno type="eISSN">1600-0625</idno>
<imprint><biblScope unit="vol">15</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="482">482</biblScope>
<biblScope unit="page" to="482">482</biblScope>
<biblScope unit="page-count">1</biblScope>
<publisher>Blackwell Publishing Ltd/Inc.</publisher>
<pubPlace>Oxford, UK; Malden, USA</pubPlace>
<date type="published" when="2006-06">2006-06</date>
</imprint>
<idno type="ISSN">0906-6705</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0906-6705</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS). Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow‐up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab. Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked (n = 1), moderate (n = 4) or null (n = 2). At week 10, five patients were evaluated and judged this efficacy as marked (n = 2), moderate (n = 2) or null (n = 1). The mean Skindex‐29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10. Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Dupuy, Alain" sort="Dupuy, Alain" uniqKey="Dupuy A" first="Alain" last="Dupuy">Alain Dupuy</name>
</region>
<name sortKey="Bachelez, Herve" sort="Bachelez, Herve" uniqKey="Bachelez H" first="Hervé" last="Bachelez">Hervé Bachelez</name>
<name sortKey="Fardet, Laurence" sort="Fardet, Laurence" uniqKey="Fardet L" first="Laurence" last="Fardet">Laurence Fardet</name>
<name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name>
<name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name>
<name sortKey="Levy, Annabelle" sort="Levy, Annabelle" uniqKey="Levy A" first="Annabelle" last="Levy">Annabelle Levy</name>
<name sortKey="Morel, Patrice" sort="Morel, Patrice" uniqKey="Morel P" first="Patrice" last="Morel">Patrice Morel</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000504 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000504 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:8A06656ED8C310D1C1359881CEBB4BFF5981988C
   |texte=   Infliximab for hidradenitis suppurativa: report of seven consecutive patients
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Infliximab for hidradenitis suppurativa: report of seven consecutive patients

Infliximab for hidradenitis suppurativa: report of seven consecutive patients

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri